Table II.
Outcome measurements among patients with prurigo nodularis receiving dupilumab (n = 14), from baseline to 1 year of treatment
| DLQI | Pruritus-NRS | MADRS-S | ||||
|---|---|---|---|---|---|---|
| Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | |
| Baseline | 15 (10–20) | 14 | 8.5 (7–9.5) | 12 | 13 (8–19) | 14 |
| 1–3 months | 6.5 (3–8) | 10 | 3 (2–6) | 9 | 6 (4–10) | 10 |
| 4–6 months | 8 (2–16) | 8 | 4 (2–7) | 7 | 5 (3–7.5) | 8 |
| 7–9 months | 5 (4–11) | 5 | 2.5 (0–6) | 4 | 5 (5–8) | 5 |
| 10–12 months | 3 (1–4) | 5 | 1.5 (0.5–3) | 4 | 4 (2–7) | 5 |
| > 12 months | 6 (4–14) | 5 | 5 (3–5.5) | 4 | 3 (0–14) | 5 |
Only patients who reported DLQI (n = 14), Pruritus-NRS (n = 12), and MADRS-S (n = 14) at baseline were included in this analysis. When patients had multiple assessments in the interval the last value was chosen, with exception of >12 months when the first value (closest to 1 year of treatment) was included. Six patients had follow-up <12 months. Missing values range 3–9.
DLQI: Dermatology Life Quality Index; Pruritus-NRS: numerical rating scale; MADRS-S: Montgomery Åsberg Depression Rating Scale-Self-report; IQR: interquartile range.